Contact
QR code for the current URL

Story Box-ID: 737324

BIOTRONIK Woermannkehre 1 12359 Berlin, Germany http://www.biotronik.com
Contact Ms Manuela Schildwächter +49 30 689051414
Company logo of BIOTRONIK
BIOTRONIK

BIOTRONIK Brings Only ProMRI Implantable Defibrillator Accepted for Ultra-High Field Imaging to World's Largest MRI Market

Japanese Patients Avail of Iperia 7 VR-T DX Single-Chamber ICD with Dual-Chamber Diagnostics and Approved for 3.0 Tesla and 1.5 Tesla Full-Body MRI Scans

(PresseBox) (Tokyo, Japan, )
BIOTRONIK, a leading manufacturer of cardiovascular medical technology that offers the world's largest portfolio of ProMRI® cardiac implants, has announced the Japanese market release of its Iperia 7 VR-T DX ProMRI single-chamber implantable cardiac defibrillator (ICD). With its DX technology, BIOTRONIK offers the world's only ICDs that collects full atrial diagnostic information with just one lead. It is also the first company to grant patient access to both ultra-high field 3.0 tesla (T), with an exclusion zone, and full-body magnetic resonance imaging (MRI) at standard 1.5 T scan strength.

This comprehensive device offers a string of benefits over alternatives. Atrial diagnostic capabilities with a single lead mean there is less likelihood of complications bought about by additional hardware. At the same time, allowing patients to undergo 3.0 T MRI scans can be critical in diagnosing conditions such as stroke, brain tumors or orthopedic conditions. Japan is the world's largest MRI market with more MRI scanners per capita than any other country: approximately 47 registered machines per one million people1.

"Approximately 60 percent of our MR conditional device patients undergo MRI examinations in order to identify potential complications," commented Dr. Toshiaki Sato from Kyorin University Hospital, Tokyo, Japan, who was one of the first to implant the Iperia DX device in a patient in Japan. "80 percent of these scans are brain MRIs. The 3.0 T MRI machine, with improved signal-to-noise ratio, was introduced in our hospital in 2010 and has been used mainly for brain MRI scans. In Japan, 3.0 T compatibility is preferred for MR conditional devices and the need for this technology will be further increased in the future."

With Iperia, inappropriate shocks may be reduced with MorphMatch morphology detection criteria and optimized anti-tachycardia pacing. This makes it easier to give a patient the appropriate level of pacing therapy he or she might need. The device also features BIOTRONIK Home Monitoring®, which allows physicians to remotely follow their patients' device status on a daily basis. The system has demonstrated the ability to detect clinically relevant events, including silent, asymptomatic arrhythmias2 and device related issues3 allowing for earlier intervention.

"The DX technology used in Iperia is based on more than a decade of engineering refinement to ensure accurate and reliable sensing of the atrial signal," added Wolf Ruhnke, Vice President at BIOTRONIK. "Integrating this with our unique Home Monitoring System for early detection, and adding the capability of high resolution 3.0 T MRI procedures, now offers patients most complete care and gives physicians the best possible treatment option."

About ProMRI

BIOTRONIK ProMRI technology enables patients with a pacemaker, implantable defibrillator, or cardiac resynchronization therapy defibrillator (CRT-D) or pacemaker (CRT-P) to undergo an MRI scan. BIOTRONIK has the broadest portfolio of cardiac devices approved for use in the MR environment on the market and is the only company to allow heart failure patients with CRT devices to take advantage of MRI scans. ProMRI technology enables pacemaker patients, and now ICD patients, to undergo full-body scans. Patients implanted with an Iperia DX device may now also undergo ultra-high field 3.0 T scans.

References
1 OECD Health Statistics 2013 http://dx.doi.org/....
2 Varma et al., TRUST Trial. (2010), 325-332.
3 Varma et al., Arrhythmia and Electrophysiology (2010) 3:428-436.

Website Promotion

Website Promotion

BIOTRONIK

One of the world's leading manufacturers of cardio and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including BIOTRONIK Home Monitoring®; the world's first 4 F-compatible 200 mm peripheral stent; Orsiro, the industry's first hybrid drug-eluting stent; and the world's first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.

For more information, visit: www.biotronik.com

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.